In Reply.—Dr Slater writes of the unending debate between the proponents of OPV and those favoring the addition or substitution of the new E-IPV. The exchange of commentaries by Drs Marcuse and me was not such a debate but a presentation of positions both favoring the addition of E-IPV. The question was a matter of timing; whether to make the addition now for the private sector only or to introduce it later when all infants and children would benefit, and when E-IPV could be integrated into our immunization schedule to include DTP and conjugate Haemophilus influenza B for infants. We agree with his conclusion that the need exists for "harnessing the special virtues of both of these excellent products." The combined schedule that eventually will be used in the United States will probably differ from that initiated in Israel (E-IPV at 2, 4, and 12 months; trivalent OPV at
KATZ SL. Postoutbreak Polio Vaccination Policy in Israel-Reply. Am J Dis Child. 1990;144(8):850–851. doi:10.1001/archpedi.1990.02150320012006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: